Lupus & antiphospholipid syndrome
Do novel inflammation biomarkers arising from routine complete blood count play a role in patients with systemic lupus erythematosus?
Authors' conclusion
Compared to healthy controls the CBC-based SIIB investigated are significantly increased in SLE patients. However, SIIB do not appear to be useful in managing SLE clinically. Nevertheless, we confirm that higher ANA titers can predict flares of SLE.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients with an available baseline complete blood count (CBC)
- Participants
- 148 patients
- Exposure
- SLE vs healthy controls and patients with other inflammatory conditions
- SLEn = 148
- Outcome
- Baseline CBC-derived systemic immune-inflammation biomarkers (NLR, SII, PIV)
- Follow-up
- Baseline
Methodological detailsmulticentre, univariable and multivariable analysis
- Multicentre
- Univariable and multivariable analysis
Main finding
As reported in the abstract
- Significantly higher in SLE than in healthy controls
- p < 0.0001
Observational data: associations, not effects.
Further findings
Baseline predictor of SLE flare (multivariable): ANA titer > 1:640
| OR (95% CI) | P value | ||
|---|---|---|---|
| ANA titer > 1:640The only significant baseline predictor | 7.6 (3.1–18.8) | P < 0.0001 | |
| 0.050.21520Odds ratio (log scale) |
Improvement of SLE following treatment
- Associated with absence of lymphopenia and ANA > 1:640
- P = 0.041
Correlation with SLEDAI-2K
- SLEDAI-2K correlated significantly with neutrophil-to-lymphocyte ratio (NLR), SII, CRP, lymphocytes and monocytes only on univariable testing
Original publication
Do novel inflammation biomarkers arising from routine complete blood count play a role in patients with systemic lupus erythematosus? Lupus. Published 22 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →